Literature DB >> 8759492

The systemic inflammatory response syndrome as a predictor of bacteraemia and outcome from sepsis.

G R Jones1, J A Lowes.   

Abstract

Criteria defining the systemic inflammatory response syndrome (SIRS) were used to assess prospectively 270 clinical episodes in which blood cultures were taken from patients in general medicine. SIRS, severe sepsis and septic shock occurred in 149 (55%), 13 (5%) and 9 (3%) episodes, respectively. However, evidence of organ hypoperfusion indicating severe sepsis was recorded as sought in only 26% of episodes of SIRS. Crude mortality at 28 days increased sequentially as more SIRS criteria were met, rising from 12% in non-SIRS blood culture episodes, to 36% when all four criteria were met. Mortality from severe sepsis and septic shock was 38% and 56%, respectively. In 61/64 (95%) episodes of clinically important bacteraemia, patients fulfilled SIRS criteria when the blood culture was taken. However, the positive predictive value of SIRS for predicting bacteraemia was only 7%. Patients who did not fulfil SIRS criteria when blood cultures were taken were at low risk of bacteraemia and comprised 45% (121/270) of the study population. Three patients in this low-risk group had bacteraemia. Mortality in bacteraemic patients with severe sepsis or septic shock who were initially treated with ineffective antibiotics for up to 48 h was 80%, compared to 42% in those always treated appropriately.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8759492     DOI: 10.1093/qjmed/89.7.515

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  36 in total

Review 1.  How do you choose antibiotic treatment?

Authors:  L Leibovici; I Shraga; S Andreassen
Journal:  BMJ       Date:  1999-06-12

Review 2.  [Surgical concepts for treatment of severe sepsis].

Authors:  O Kollmar; M K Schilling
Journal:  Anaesthesist       Date:  2003-12       Impact factor: 1.041

Review 3.  Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis.

Authors:  Mical Paul; Vered Shani; Eli Muchtar; Galia Kariv; Eyal Robenshtok; Leonard Leibovici
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

4.  Clinical impact of preincubation of blood cultures at 37°C.

Authors:  Lieven B van der Velden; Fidel J Vos; Johan W Mouton; Patrick D Sturm
Journal:  J Clin Microbiol       Date:  2010-11-10       Impact factor: 5.948

5.  Sepsis in standard care: patients' characteristics, effectiveness of antimicrobial therapy and patient outcome--a cohort study.

Authors:  Franz Ratzinger; Katharina Eichbichler; Michael Schuardt; Irene Tsirkinidou; Dieter Mitteregger; Helmuth Haslacher; Thomas Perkmann; Klaus G Schmetterer; Georg Doffner; Heinz Burgmann
Journal:  Infection       Date:  2015-04-04       Impact factor: 3.553

6.  Clinical Characteristics and Antimicrobial Susceptibility Pattern of Hospitalized Patients with Community Acquired Urinary Tract Infections at a Regional Hospital in Taiwan.

Authors:  Luke F Chen; Chun-Ting Chiu; Jui-Yo Lo; Si-Yuan Tsai; Li-Shiu Weng; Deverick J Anderson; Huan-Sheng Chen
Journal:  Healthc Infect       Date:  2013-12-16

7.  Intensive Care Society Clinical Practice Free Paper Presentations.

Authors: 
Journal:  J Intensive Care Soc       Date:  2015-03-17

Review 8.  Critical care in the emergency department: severe sepsis and septic shock.

Authors:  P A Nee
Journal:  Emerg Med J       Date:  2006-09       Impact factor: 2.740

9.  Does gram-negative bacteraemia occur without endotoxaemia? A meta-analysis using hierarchical summary ROC curves.

Authors:  J C Hurley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-29       Impact factor: 3.267

10.  Incidence and long-term outcome of sepsis on general wards and in an ICU at the General Hospital of Vienna: an observational cohort study.

Authors:  Thomas Stiermaier; Harald Herkner; Selma Tobudic; Karin Burgmann; Thomas Staudinger; Peter Schellongowski; Heinz Burgmann
Journal:  Wien Klin Wochenschr       Date:  2013-05-18       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.